Longboard Pharmaceuticals Inc Quick Ratio (LBPH) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Longboard Pharmaceuticals Inc   (NASDAQ: LBPH)

Longboard Pharmaceuticals Inc 's Quick Ratio

LBPH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2024, Quick Ratio fell to 15.72 below Longboard Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 21 other companies have achieved higher Quick Ratio than Longboard Pharmaceuticals Inc in third quarter 2024. While Quick Ratio total ranking has improved so far during the Q3 2024 to 98, from total ranking in the second quarter 2024 at 125.

Explain Quick Ratio?
How much Cash & cash equivalents LBPH´s has?
What are LBPH´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LBPH Quick Ratio (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3
Y / Y Current Liabilities Change 173.42 % 86.52 % 42.15 % 11.52 % -17.67 %
Y / Y Cash & cash equivalent Change 414.94 % 383.56 % 321.73 % -28.25 % -27.55 %
Quick Ratio MRQ 15.72 20.69 31.2 4.96 8.35
LBPH's Total Ranking # 98 # 125 # 79 # 570 # 414
Seq. Current Liabilities Change 24.53 % 43.22 % 5.28 % 45.62 % -15.05 %
Seq. Cash & cash equivalent Change -5.39 % -5.04 % 561.97 % -13.42 % -11.15 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 22
Healthcare Sector # 36
Overall Market # 98


Quick Ratio Statistics
High Average Low
36.31 17.09 4.96
(Jun 30 2021)   (Dec 31 2023)




Financial Statements
Longboard Pharmaceuticals Inc 's Current Liabilities $ 18 Millions Visit LBPH's Balance sheet
Longboard Pharmaceuticals Inc 's Cash & cash equivalent $ 288 Millions Visit LBPH's Balance sheet
Source of LBPH's Sales Visit LBPH's Sales by Geography


Cumulative Longboard Pharmaceuticals Inc 's Quick Ratio

LBPH's Quick Ratio for the trailling 12 Months

LBPH Quick Ratio

 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 73.61 % 29.5 % 9.39 % 1.54 % 10.03 %
Y / Y Cash & cash equivalent TTM Growth 266.42 % 157.12 % 58.41 % -25.81 % -28.51 %
Quick Ratio TTM 18.11 17.6 14.09 7.71 8.58
Total Ranking TTM # 2594 # 2555 # 2745 # 2974 # 3026
Seq. Current Liabilities TTM Growth 28.04 % 19.71 % 9.65 % 3.3 % -4.5 %
Seq. Cash & cash equivalent TTM Growth 31.82 % 49.49 % 100.5 % -7.27 % -7.5 %

Quick ratio ranking by company, industry and sector >> Back to LBPH Financial Strength Comparisons >> Go to Compare LBPH Quick Ratio to its Competitors

On the trailing twelve months basis LBPH Cash & cash equivalent more than doubled by 414.94 % in Q3 2024 year on year, faster than Current Liabilities, this led to increase in in Longboard Pharmaceuticals Inc 's Quick Ratio to 18.11, above LBPH average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 415 other companies have achieved higher Quick Ratio than Longboard Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 2555 to 2594.

Explain Quick Ratio?
How much Cash & cash equivalents LBPH´s has?
What are LBPH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 416
Healthcare Sector # 834
Within the Market # 2594


trailing twelve months Quick Ratio Statistics
High Average Low
27.35 14.6 7.71
(Dec 31 2021)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2024 MRQ Cash & cash equivalentSep 30 2024 MRQ Current Liabilities
Third Harmonic Bio Inc   41.91 $ 296.093  Millions$ 7.065  Millions
Bioage Labs Inc   41.30 $ 334.474  Millions$ 8.098  Millions
Contineum Therapeutics Inc   41.18 $ 213.911  Millions$ 5.195  Millions
Sagimet Biosciences inc   38.35 $ 152.486  Millions$ 3.976  Millions
Janux Therapeutics Inc   38.32 $ 658.031  Millions$ 17.173  Millions
Viking Therapeutics Inc   36.91 $ 930.440  Millions$ 25.205  Millions
Context Therapeutics Inc   36.36 $ 84.802  Millions$ 2.332  Millions
Bicara Therapeutics Inc   35.96 $ 520.758  Millions$ 14.481  Millions
Immunome Inc   35.16 $ 240.130  Millions$ 6.830  Millions
Design Therapeutics Inc   34.19 $ 254.074  Millions$ 7.432  Millions
Terns Pharmaceuticals Inc   32.67 $ 372.777  Millions$ 11.412  Millions
Alumis inc   30.56 $ 361.870  Millions$ 11.840  Millions
Jade Biosciences Inc   30.15 $ 146.539  Millions$ 4.860  Millions
Essa Pharma inc   29.87 $ 103.721  Millions$ 3.473  Millions
Tyra Biosciences Inc   29.11 $ 360.130  Millions$ 12.373  Millions
Crinetics Pharmaceuticals Inc   27.95 $ 1,496.824  Millions$ 53.562  Millions
Structure Therapeutics Inc   27.38 $ 915.286  Millions$ 33.434  Millions
Oramed Pharmaceuticals Inc  26.99 $ 142.300  Millions$ 5.273  Millions
Edgewise Therapeutics inc   25.98 $ 492.536  Millions$ 18.957  Millions
Mbx Biosciences Inc   25.37 $ 277.063  Millions$ 10.920  Millions
Moonlake Immunotherapeutics  24.60 $ 493.925  Millions$ 20.081  Millions
Palvella Therapeutics Inc   24.17 $ 19.363  Millions$ 0.801  Millions
Onkure Therapeutics Inc   23.60 $ 76.668  Millions$ 3.248  Millions
Nuvalent Inc   22.85 $ 1,168.309  Millions$ 51.132  Millions
Arca Biopharma Inc  22.78 $ 410.875  Millions$ 18.039  Millions
Aprea Therapeutics Inc   22.75 $ 26.250  Millions$ 1.154  Millions
Novabridge Biosciences  22.70 $ 173.398  Millions$ 7.638  Millions
Ideaya Biosciences Inc   22.63 $ 920.029  Millions$ 40.659  Millions
Lixte Biotechnology Holdings Inc   22.46 $ 1.638  Millions$ 0.073  Millions
Ventyx Biosciences Inc   22.34 $ 274.825  Millions$ 12.303  Millions

Date modified: 2026-09-08T20:32:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.